Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Amid Earnings Deluge
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1% and the actively traded Invesco QQQ Trust (QQQ) was 0.6% higher in Wednesday's premarket activity, as earnings continue t
MT NewswiresApr 24 07:53 ET
Express News | Reported Earlier, Centessa Pharmaceuticals Prices $100M Public Offering Of 10,810,810 American Depositary Shares At $9.25/ADS
Moomoo 24/7Apr 24 02:18 ET
Centessa Pharmaceuticals Eyes $100 Million in ADS Offering
Centessa Pharmaceuticals (CNTA) said Tuesday it is seeking to raise $100 million from an underwritten public offering of American Depositary Shares, each representing one ordinary share. The proposed
MT NewswiresApr 23 18:00 ET
Express News | Announces $100M Proposed Public Offering Of American Depositary Shares
Moomoo 24/7Apr 23 16:18 ET
Press Release: Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA
Dow JonesApr 23 16:17 ET
Centessa Pharmaceuticals Advances Narcolepsy Drug Trials
TipRanksApr 22 07:32 ET
Express News | The FDA Has Cleared Centessa Pharmaceuticals' Investigational New Drug Application To Initiate A Phase 1 First-in-human, Clinical Trial Of ORX750 For Narcolepsy
Moomoo 24/7Apr 22 07:09 ET
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
BOSTON and LONDON, April 22, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for
GlobeNewswireApr 22 07:00 ET
Buy Rating Affirmed for Centessa Pharmaceuticals Amid Promising ORX750 Prospects and Favorable Trial Results
TipRanksApr 12 01:38 ET
Analysts' Top Healthcare Picks: AstraZeneca (AZN), Centessa Pharmaceuticals (CNTA)
TipRanksApr 10 07:11 ET
Express News | BMO Capital Maintains Outperform on Centessa Pharmaceuticals, Maintains $15 Price Target
Moomoo 24/7Apr 1 12:25 ET
Centessa Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/01/2024 36.49% BMO Capital $15 → $15 Maintains Outperform 11/15/2023 0.09% Jefferies $4 → $11 Upgrades
BenzingaApr 1 12:24 ET
Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Centessa Pharmaceuticals (CNTA)
TipRanksApr 1 10:20 ET
Centessa Pharmaceuticals PLC (CNTA) Earnings: A Detailed Look at Q4 and Full-Year 2023 Results
Yahoo FinanceMar 28 18:11 ET
Centessa Pharmaceuticals Q4 EPS $(0.38) Beats $(0.48) Estimate
Centessa Pharmaceuticals (NASDAQ:CNTA) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.48) by 20.83 percent. This is a 15.56 percent increase over losse
BenzingaMar 28 16:56 ET
Centessa Pharmaceuticals 4Q Loss/Shr 38c >CNTA
Centessa Pharmaceuticals 4Q Loss/Shr 38c >CNTA
Dow JonesMar 28 16:29 ET
Press Release: Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023 -- Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 stu
Dow JonesMar 28 16:28 ET
Centessa Pharmaceuticals PLC Chief People Officer Sells Company Shares
Yahoo FinanceMar 27 01:26 ET
Centessa Pharmaceuticals(CNTA.US) Officer Sells US$607.96K in Common Stocks
$Centessa Pharmaceuticals(CNTA.US)$ Officer Anderson Karen M. sold 51,160 shares of Common Stocks on Mar 25, 2024 at an average price of $11.8835 for a total value of $607.96K.Source: Announcement Wha
moomoo NewsMar 26 17:00 ET
Centessa Pharmaceuticals Insider Sold Shares Worth $607,960, According to a Recent SEC Filing
Karen M. Anderson, Chief People Officer, on March 25, 2024, sold 51,160 shares in Centessa Pharmaceuticals (CNTA) for $607,960. Following the Form 4 filing with the SEC, Anderson has control over a to
MT NewswiresMar 26 16:25 ET
No Data
No Data